Yeongjin Hong

1 ta ish

CNCure Biotech, Inc., Jeollanam-do, Republic of Korea

1. The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy

   Ying Zhang, V. Akhil, Ho Seong Seo +8

   MaqolaCancer Research and TreatmentsTheranostics20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.000480